Sequential combination chemotherapy for malignant germ cell tumors of the ovary

Cancer

Volumn 61, Issue 5, 1988, Pages 913-918

  Germa, Josep R ^a   Piera, Josep M ^a   Barnadas, Agusti ^a   Badia, Josep ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; VINBLASTINE; VINCRISTINE;

CLINICAL ARTICLE; DYSGERMINOMA; FEMALE; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; YOLK SAC TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PROGNOSIS; REOPERATION;

EID: 0023871057     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19880301)61:5<913::AID-CNCR2820610510>3.0.CO;2-9     Document Type: Article

References (39)

1. Epidemiology of germ cell tumors
2. Endodermal sinus tumor of the ovary: A clinical and pathological analysis of 71 cases
3. Malignant germ cell tumors of the ovary
4. Ovarian extraembryonal teratoma: I. Endodermal sinus tumor
5. Ovarian extraembryonal teratoma: II. Endodermal sinus tumor mixed with other germ cell tumors
6. Study of ovarian dysgerminoma with emphasis on the role of radiation therapy
7. Dysgerminoma: An analysis of 105 cases
8. Endodermal sinus tumor: A report of two sustained remissions treated postoperatively with a combination of actinomycin‐D, 5‐Fluorouracil and cyclophosphamide
9. Germ cell malignancies of the ovary
10. Germ cell malignancies of the ovary
11. Observations on chemotherapy of granulosa cell carcinomas and malignant ovarian teratomas
12. Advances in chemotherapy for gynecologic cancer
13. Treatment of malignant ovarian germ cell tumors: Response to vincristine, dactinomycin, and cyclophosphamide
14. Improved prognosis in children with ovarian cancer following modified VAC (vincristine sulfate, dactinomycin, and cyclophosphamide) chemotherapy
15. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin and cyclophosphamide
16. Combination cisplatin, vinblastine and bleomycin therapy (PVB) for malignant germ‐cell tumors of the ovary
17. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary
18. Treatment of malignant non dysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin and cisplatin
19. Potential for cure in metastatic ovarian teratomas and dysgerminomas
20. Further advances in the management of malignant teratomas in the testis and other sites
21. Immature (malignant) teratoma of the ovary: A clinical and pathologic study of 58 cases
22. Reporting results of cancer treatment
23. Treatment of poor prognosis nonseminomatous testicular cancer with a “high‐dose” platinum combination chemotherapy regimen
24. Acute leukaemia after alkylating‐agent therapy of ovarian cancer
25. Vascular and other complications of chemotherapy for testicular cancer
26. Phase II evaluation of Adriamycin in human neoplasia
27. Tumour marker levels and prognosis in malignant teratoma of the testis
28. Rationale for the use of alternating non‐cross‐resistant chemotherapy
29. Pregnancy following removal and chemotherapy for ovarian endodermal sinus tumor
30. Case report: Pregnancy following chemotherapy for an ovarian immature embryonal teratoma
31. Pregnancy following combination chemotherapy for a mixed germ cell tumor of the ovary
32. Pregnancy after treatment of endodermal sinus tumor: Case report with five‐year survival
33. Second‐look laparotomy in the management of malignant germ cell tumors of the ovary
34. The development of non‐germ cell malignancies within germ cell tumors: A clinicopathologic study of 11 cases
35. Retroperitoneal malignancies several years after initial treatment of germ cell cancer of the testis
36. Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy
37. Histology and DNA contents of a secondary malignancy arising in a mature residual lesion six years after chemotherapy for a disseminated nonseminomatous testicular tumor